Advertisement

Topics

Biocad’s rituximab ‘similar biologic’ recommended for approval in India

05:32 EDT 18 Aug 2017 | Generics and Biosimilars Initiative

Russian biotechnology company Biocad announced on 4 July 2017 that it would ‘soon’ receive marketing approval for its rituximab ‘similar biologic’ in India under the trade name Acellbia.

Original Article: Biocad’s rituximab ‘similar biologic’ recommended for approval in India

NEXT ARTICLE

More From BioPortfolio on "Biocad’s rituximab ‘similar biologic’ recommended for approval in India"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...